

file w/ #4

Sheet 01 of 02

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce	Docket No. PENN-0701	Serial No. 09/419,328
	Applicant ALAIN H. ROOK	
	Filing Date OCTOBER 15, 1999	Group 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


FH ↓	AA	Brunda, et al., "Antitumor and Antimetastatic Activity of Interleukin 12 against Murine Tumors", <i>J. Exp. Med.</i> 1993 178:869-879
	AB	Diamandidou, E., et al., "Mycosis Fungoides and Sezary Syndrome", <i>Blood</i> 1996 88:2385-2409
	AC	Haku, et al., "Interleukin-12-Mediated Killer Activity in Lung Cancer Patients", <i>Cytokine</i> 1997 9:846-852
	AD	Hiramatsu, K., et al., "Generation of killer activity by interleukin-12 of mononuclear cells in malignant pleural effusions due to lung cancer", <i>Cancer Immunol. Immunother.</i> 1998 46:1-6
	AE	Hsieh, C.S., et al., "Development of T _H 1 CD4 ⁺ T Cells Through IL-12 Produced by Listeria-Induced Macrophages", <i>Science</i> 1993 260:547-549
	AF	Nishimura, et al., "Systemic in vivo antitumor activity of interleukin-12 against both transplantable and primary tumor", <i>Immunol. Lett.</i> 1995 48:149-152
	AG	Rook, et al., "Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses", <i>Blood</i> 1999 94:902-908
	AH	Rook, et al., "The Immunopathogenesis of Cutaneous T-Cell Lymphoma", <i>Arch. Dermatol.</i> 1993 129:486
	AI	Rook, et al., "IL-12 Reverses Cytokine and Immune Abnormalities in Sezary Syndrome ¹ ", <i>J. Immunol.</i> 1995 154:1491-1498

EXAMINER

Fora Hamed

DATE CONSIDERED

9/27/00



Sheet 02 of 02

Form PTO-1449 Modified

List of Patents and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce

Docket No.
PENN-0701

Serial No.
09/419,328

Applicant
ALAIN H. ROOK

Filing Date
OCTOBER 15, 1999

Group
1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

F#	AJ	Rook, et al., "The Potential Therapeutic Role of Interleukin-12 in Cutaneous T-Cell Lymphoma ^α ", <i>Ann. NY Acad. Sci.</i> 1996 795:310-318
	AK	Rook, et al., "Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis", <i>Clin. Ex. Immunol.</i> 1997 107:16-20
	AL	Sahin, et al., "Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors", <i>Cancer Immunol. Immunother.</i> 1996 42:9-14
	AM	Seo N., et al., "Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sezary syndrome: its enhancement by interferon-gamma (IFN-γ) and IL-12 and fluctuations in association with disease activity", <i>Clin. Exp. Immunol.</i> 1998 112:403-409
	AN	Verbik, et al., "In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma", <i>Clin. Exp. Metastasis</i> 1996 42:219-229
	AO	Vowels, et al., "Aberrant Cytokine Production by Sezary Syndrome Patients: Cytokine Secretion Pattern Resembles Murine Th2 Cells", <i>J. Invest. Dermatol.</i> 1992 99:90-94
	AP	Vowels, et al., "Th2 cytokine mRNA Expression in Skin in Cutaneous T-Cell Lymphoma", <i>J. Invest. Dermatol.</i> 1994 103:669-673
	AQ	Vowels, et al., "Normalization of Cytokine Secretion Patterns and Immune Function Following Disappearance of Malignant Clone from the Peripheral Blood of a Sezary Syndrome (SzS) Patient", <i>J. Invest. Dermatol.</i> 1993 100:556
EXAMINER	DATE CONSIDERED 9/27/00	